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Abstract 
In the last few years, monoclonal antibodies have revolutionized the treatment of retinal neovascular diseases. More 
recently, a different class of drugs, fusion proteins, has provided an alternative treatment strategy with pharmacologi-
cal differences. In addition to commercially available aflibercept, two other drugs, ziv-aflibercept and conbercept, 
have been studied in antiangiogenic treatment of ocular diseases. In this scenario, a critical review of the currently 
available data regarding fusion proteins in ophthalmic diseases may be a timely and important contribution. Afliber-
cept, previously known as VEGF Trap Eye, is a fusion protein of VEGF receptors 1 and 2 and a treatment for several 
retinal diseases related to angiogenesis. It has firmly joined ranibizumab and bevacizumab as an important thera-
peutic option in the management of neovascular AMD-, DME- and RVO-associated macular edema. Ziv-aflibercept, 
a systemic chemotherapeutic agent approved for the treatment of metastatic colorectal cancer, has recently drawn 
attention because of its potential for intravitreal administration, since it was not associated with ERG-related signs of 
toxicity in an experimental study and in human case reports. Conbercept is a soluble receptor decoy that blocks all 
isoforms of VEGF-A, VEGF-B, VEGF-C, and PlGF, which has a high binding affinity for VEGF and a long half-life in vitre-
ous. It has been studied in a phase three clinical trial and has shown efficacy and safety. This review discusses three 
fusion proteins that have been studied in ophthalmology, aflibercept, ziv-aflibercept and conbercept, with emphasis 
on their clinical application for the treatment of retinal diseases.
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Introduction
Vascular endothelial growth factor (VEGF) is a 36- to 
46-kDa homodimeric glycoprotein that acts as an angio-
genic cytokine, inducing mitosis [1]. It has six members, 
VEGF-A to -E, and placental growth factor (PlGF), of 
which VEGF-A is the most important cytokine involved 
in angiogenesis. There are several isoforms of VEGF-
A in humans: VEGF121, VEGF145, VEGF165, VEGF183, 
VEGF189 and VEGF206. Of these, VEGF165 is the most 
common VEGF-A isoform and the most important for 
angiogenesis [2]. Three VEGF receptor (VEGFR) sub-
types have been identified: VEGFR 1–3, among which 
VEGFR-1 binds VEGF with the highest affinity, while 
VEGFR-2 is the most important in angiogenesis [2].
Many cell types in the retina produce VEGF. These 
include the retinal pigment epithelium (RPE), vascular 
endothelial cells, pericytes, retinal neurons, Müller cells 
and astrocytes [3, 4]. VEGF is secreted by the RPE and 
retinal cells in response to hypoxia secondary to ischemic 
retinal disorders. Upregulation of VEGF results in angio-
genesis, increased vascular permeability, and the produc-
tion of pro-inflammatory cytokines [5].
Over the past decade, the use of intravitreal pharma-
cotherapy to block VEGF has become common and has 
significantly improved visual outcomes in patients with 
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neovascular age-related macular degeneration (AMD), 
diabetic macular edema (DME) and retinal vein occlu-
sion (RVO)-associated macular edema (ME) [6–8]. These 
retinal diseases are characterized by the production of 
increased levels of intraocular VEGF and development of 
ME resulting in dysfunction of central and sharp vision. 
VEGF also mediates the development of neovasculariza-
tion in these conditions and may lead to severe irreversi-
ble vision loss. The administration of an anti-VEGF agent 
in the vitreous cavity of patients with these disorders 
lowers intraocular VEGF, reduces vascular permeabil-
ity and is associated with arrested growth of and leakage 
from neovessels in choroidal neovascularization (CNV) 
[6, 9].
VEGF blockers used to treat eye diseases have included 
an aptamer, a humanized monoclonal antibody, an anti-
body fragment, and, more recently, cytokine traps [6, 10–
12]. The purpose of this review is to provide an overview 
of three fusion proteins that have been studied for the 
treatment of retinal diseases: aflibercept, ziv-aflibercept 
and conbercept.
Fusion proteins: history, chemistry, production, 
and biology
In 2002, Holash et al. published the first paper reporting 
the development and in vivo study of VEGF Trap for can-
cer treatment. VEGF Trap was created by fusing the first 
three immunoglobulin (Ig) domains of VEGFR-1 to the 
Fc region of human IgG1. Three additional VEGF traps 
were then engineered on the basis of that initial molecule: 
the VEGF Trap B1 (in which a highly basic 10-amino acid 
sequence was removed from the third Ig domain of the 
parental trap), the VEGF Trap B2 (in which the entire 
first Ig domain from VEGF Trap B1 was removed), and 
VEGF Trap R1R2 (the result of the fusion of the second 
Ig domain of VEGFR-1 with the third domain of VEGFR-
2). These modifications enhanced R1R2 trap affinity 
for VEGF-A. The initial parental VEGF Trap had very 
high affinity for VEGF-A and PlGF, but was a strongly 
positively charged molecule that bound to the extracel-
lular matrix in addition to VEGF-A and PlGF. Modifica-
tions resulted in a less positively charged molecule that 
retained high affinity for VEGF-A and VEGF-B as well 
as PlGF, but did not specifically bind to the extracellular 
matrix [13].
The current aflibercept, previously called VEGF Trap 
Eye, evolved from the parental VEGF Trap studied by 
Holash et  al. This fully human protein consists of an 
all human amino acid sequence, which minimizes the 
potential for immunogenicity in human patients [13]. 
Aflibercept (Eylea; Regeneron, Tarrytown, NY, USA, and 
Bayer, Leverkusen, Germany) is a dimeric glycoprotein 
with a protein molecular weight of 96.9 kDa. It contains 
approximately 15 % glycosylation to give a total molecu-
lar weight of 115 kDa. As a designed molecule featuring 
optimal pharmacologic characteristics to inhibit intraoc-
ular VEGF, intravitreal aflibercept injection (IAI) offers 
improved binding affinity and superior pharmacoki-
netics in an iso-osmotic formulation. Aflibercept may 
have approximately 100-fold greater binding affinity for 
VEGF-A than does either bevacizumab or ranibizumab 
[9, 10]. It binds to all VEGF-A isoforms and the related 
VEGFR-1 ligands, VEGF-B and PlGF, and it is the only 
United States Food and Drug Administration (FDA)-
approved VEGF Trap for intravitreal use [9, 14].
Ziv-aflibercept (Zaltrap; co-developed by Sanofi-
Aventis and Regeneron Pharmaceuticals, Inc, Tarrytown, 
NY, USA), is identical to aflibercept, except for its excipi-
ents and higher osmolarity. While aflibercept is available 
in a single-use glass vial designed to provide 0.05  ml of 
40  mg/ml solution (2  mg) for intravitreal injection, ziv-
aflibercept is available as 100 mg per 4 ml (25 mg per ml) 
solution or 200 mg per 8 ml (25 mg per ml) solution, in 
a single-use vial. Aflibercept is iso-osmolar, whereas ziv-
aflibercept is hyperosmolar (1000 mOsm/l) relative to the 
vitreous [15, 16].
In 2012, ziv-aflibercept received United States FDA 
approval for use in combination with FOLFIRI (folinic 
acid, fluorouracil and irinotecan) in patients with 
metastatic colorectal cancer that is resistant to or has 
progressed after oxaliplatin-based regimens such as FOL-
FOX (folinic acid, fluorouracil, oxaliplatin) [16]. Its intra-
vitreal off-label use in humans was not associated with 
toxicity, inflammation or higher rate of cataract induction 
[11, 17, 18]. Although this drug has a higher osmolarity 
when compared to aflibercept, serum and intraocular 
osmolarity may not be significantly altered after intravit-
real injection of ziv-aflibercept [19].
In 2008, Zhang et al. published the first study of con-
bercept (KH902) (Lumitin; Chengdu Kanghong Bio-
tech, Ltd., Sichuan, People’s Republic of China) in an 
experimental CNV monkey model [20]. Conbercept is 
a full human DNA sequence with a molecular weight of 
143 kDa produced with Chinese hamster ovary cells, and 
it combines ligand-binding elements taken from extracel-
lular domain 2 of VEGF receptors 1 (Flt-1) and extracel-
lular domain 3 and 4 of VEGF receptors 2 (KDR) fused to 
the Fc portion of human IgG1 [20–22]. This drug binds 
VEGF dimers in a 1:1 ratio with a “two-fisted grasp” 
that resembles the action of aflibercept. The difference 
between conbercept and aflibercept is that the former 
also contains domain 4 of VEGFR-2, which was proved 
in previous studies to be essential to the receptor [10, 23, 
24]. Domain 4 does not participate in ligand binding but 
structure analysis of ligand-bound VEGFR has revealed 
that this domain might be involved in specific homotypic 
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interactions of the ligand-bound receptor, stabilizing 
receptor dimers and locking VEGF to the receptor in a 
rigid manner [20]. A preclinical study suggested that 
conbercept may have an affinity 50-fold higher for VEGF 
compared to bevacizumab and that it could be equally 
more efficient in inhibiting the proliferation of human 
umbilical vein endothelial cells induced by VEGF [20]. 
Like aflibercept and ziv-aflibercept, conbercept shows 
strong antiangiogenetic effects by binding with high 
affinity and neutralizing VEGF-A, all its isoforms, and 
PlGF [12].
Comparative table shows the structural differences 
between the three fusion proteins available for treatment 
of retinal diseases (Table 1).
Clinical application of fusion proteins 
in ophthalmology for treatment of retinal diseases
Aflibercept
The United States FDA approved Aflibercept in Novem-
ber 2011 for the treatment of neovascular AMD, in Octo-
ber 2014 for ME following RVO, and in March 2015 for 
the treatment of DME [9, 14, 25–27].
To date, large phase 3 studies have been conducted to 
evaluate the efficacy and safety of intravitreal aflibercept 
for exudative AMD. The VEGF Trap-Eye: Investigation of 
efficacy and safety in wet AMD (VIEW 1 and 2) recruited 
treatment-naive patients with neovascular AMD from 
362 centers worldwide [14]. From baseline to week 52, 
patients received 0.5  mg intravitreal ranibizumab every 
4  weeks (Rq4), 2  mg aflibercept every 4  weeks (2q4), 
0.5 mg aflibercept every 4 weeks (0.5q4), or 2 mg afliber-
cept every 8  weeks (2q8) after 3 monthly injections. 
During weeks 52 through 96, patients received their 
original dosing assignment using an as-needed regimen 
with defined retreatment criteria and mandatory dosing 
at least every 12 weeks. All aflibercept and ranibizumab 
groups were equally effective in improving best-cor-
rected visual acuity (BCVA) and maintaining BCVA (lost 
<15 letters from baseline) at 96  weeks. The 2q8 afliber-
cept group was similar to ranibizumab in visual acuity 
(VA) outcomes during 96 weeks, but with an average of 
5 fewer injections [14]. Over the 2 years of treatment, a 
generally favorable safety profile was observed for both 
intravitreal aflibercept and ranibizumab. The incidence 
of ocular treatment-emergent adverse events (AE) was 
balanced across all treatment groups, with the most fre-
quent events associated with the injection procedure, 
the underlying disease, the aging process, or a combina-
tion thereof. The incidences of arterial thromboembolic 
events and death were similar across all treatment groups 
[14].
In two parallel phase 3 DME studies, VISTADME and 
VIVIDDME, eyes were randomized in a 1:1:1 ratio to 
receive either 2  mg IAI every 4  weeks (2q4), 2  mg IAI 
every 8 weeks after 5 initial monthly doses (from baseline 
to week 16) with sham injections on non-treatment vis-
its (2q8), or macular laser photocoagulation at baseline 
and sham injections at every visit [7]. The results dem-
onstrated that aflibercept given either every 4 or 8 weeks 
was superior to laser alone, and results in both showed 
significant VA gains and prevention of severe VA loss. 
The mean change from baseline BCVA in the 2q4 and 2q8 
groups compared with the laser group was +12.5 ± 9.5 
and +10.7 ± 8.2 letters vs +0.2 ± 12.5 letters in VISTA 
(P < 0.0001), and +10.5 ± 9.5 and +10.7 ± 9.3 letters vs 
+1.2 ±  10.6 letters (P  <  0.0001) in VIVID, respectively 
[7]. The percentage of eyes in the laser group that lost 
≥15 letters of vision replicated the 10 % loss reported by 
the early treatment diabetic retinopathy study (ETDRS) 
[7, 28]. Overall incidences of ocular and nonocular AE 
were similar across treatment groups [7].
The Diabetic Retinopathy Clinical Research Network 
(DRCR.net), sponsored by the National Institutes of 
Health, conducted a multicenter, randomized clinical 
trial at 89 clinical sites in the United States to compare 
the efficacy and safety of intravitreous aflibercept, bevaci-
zumab, and ranibizumab for the treatment of DME caus-
ing decreased VA. The study drugs were injected into 
the study eyes at baseline and then every 4 weeks unless 
VA was 20/20 or better with a central subfield thickness 
below the eligibility threshold and there was no improve-
ment or worsening in response to the past two injections. 
Laser photocoagulation therapy (focal, grid, or both) was 
initiated at or after the 24-week visit for persistent DME. 
Between August 2012, and August 2013, 660 participants 
were randomly assigned to receive aflibercept 2.0  mg 
(224 participants), bevacizumab 1.25 mg (218), or ranibi-
zumab 0.3  mg (218). The median number of injections 
was 9 or 10 in the three groups. The mean improvement 
in the VA letter score at 1 year was greater with afliber-
cept than with bevacizumab or ranibizumab (13.3 vs 9.7 
and 11.2, respectively; P < 0.001 for aflibercept vs bevaci-
zumab and P = 0.03 for aflibercept vs ranibizumab), but 
the relative effect varied according to initial VA. At the 
1-year visit, the central subfield thickness decreased, on 
average, by 169 ± 138 μm with aflibercept, 101 ± 121 μm 
with bevacizumab, and 147 ± 134 μm with ranibizumab. 
Injection-related infectious endophthalmitis occurred in 
one aflibercept-treated eye and one ranibizumab-treated 
eye (both nonstudy eyes) and no bevacizumab-treated 
eyes. Through 1  year, the rate of serious adverse events 
was similar in the three treatment groups (P = 0.40), as 
was the rate of hospitalization (P = 0.51) [29].
Intravitreal aflibercept has also been investigated 
for the treatment of ME secondary to central reti-
nal vein occlusion (CRVO) in two parallel trials, the 
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COPERNICUS and GALILEO studies, performed in the 
United States and in Europe and Asia/Pacific, respec-
tively [8, 30, 31]. In the GALILEO study, patients were 
randomized to receive either 2  mg IAI or sham in the 
study eye once every 4 weeks for 20 weeks, for a total of 
six doses. From week 24 to week 48, patients in the IAI 
group were evaluated every 4 weeks and received afliber-
cept as needed or pro re nata (PRN) if they met prespeci-
fied retreatment criteria [8]. The proportion of patients 
who gained ≥ 15 letters in the intravitreal aflibercept and 
sham groups was 60.2 vs 22.1 % at week 24 (P < 0.0001), 
60.2 vs 32.4 % at week 52 (P < 0.001), and 57.3 vs 29.4 % 
at week 76 (P  <  0.001). The COPERNICUS study was a 
trial parallel to GALILEO, differing in the timing of the 
IAI. Patients received IAI 2 mg (IAI 2q4) or sham injec-
tions every 4 weeks up to week 24. During weeks 24 to 
52, patients from both arms were evaluated monthly 
and received IAI PRN (IAI 2q4 + PRN and sham + IAI 
PRN). During weeks 52 to 100, patients were evaluated at 
least quarterly and received IAI PRN. The most frequent 
ocular severe adverse event (SAE) from baseline to week 
100 was vitreous hemorrhage (0.9 vs 6.8  % in the IAI 
2q4 + PRN and sham + IAI PRN groups, respectively) [8, 
30, 31]. Overall, the COPERNICUS study demonstrated 
similar effects as those seen in GALILEO study in visual 
and anatomic improvements with IAIs after switching 
from monthly dosing [30].
The VIBRANT study was conducted to compare the 
efficacy and safety of IAI with macular grid laser pho-
tocoagulation for the treatment of ME after branch 
retinal vein occlusion (BRVO) [25]. It showed that 
monthly IAI provided significantly greater visual ben-
efit and reduction in central retinal thickness (CRT) 
at 24  weeks than did grid laser. The proportion of eyes 
that gained ≥ 15 ETDRS letters from baseline at week 24 
was 52.7 % in the IAI group compared with 26.7 % in the 
laser group (P =  0.0003). The mean improvement from 
baseline BCVA at week 24 was 17.0 ETDRS letters in 
the IAI group and 6.9 ETDRS letters in the laser group 
(P < 0.0001). The mean reduction in CRT from baseline 
at week 24 was 280.5 µm in the IAI group and 128.0 µm 
in the laser group (P < 0.0001). Traumatic cataract in an 
IAI patient was the only ocular SAE that occurred. The 
incidence of nonocular SAE was 8.8 % in the IAI group 
and 9.8 % in the laser group [25].
Ziv-aflibercept
Ziv-aflibercept received FDA approval in August 2012 
for the treatment of metastatic colorectal carcinoma that 
is resistant to or has progressed on an oxaliplatin-based 
regimen [16]. Due to its mechanism of action, there is 
growing interest in using intravitreal ziv-aflibercept as an 
antiangiogenic agent for ophthalmic VEGF-related dis-
eases [17].
Malik et al. exposed human RPE cells for 24 h to four 
anti-VEGF drugs (bevacizumab, ranibizumab, aflibercept 
and ziv-aflibercept) at 1/2, 1, 2 and 10× clinical concen-
tration. At clinical doses (1×) there was no decrease in 
cell viability in all four drug groups [32]. In an experi-
mental study, nine rabbits were given an intravitreal 
injection of 0.05 ml ziv-aflibercept (25 mg/ml) [19]. There 
were no associated complications such as cataract and 
retinal detachment (RD). All eyes showed no signs of 
toxicity on funduscopy, optical coherence tomography 
(OCT) (Fig. 1), and full-field electroretinogram (ERG) 1 
or 7 days after the procedure. There were also no changes 
Fig. 1 Spectral-domain OCT 7 days after intravitreal injection of 0.05 mL of ziv-aflibercept (25 mg/mL) (a) or aflibercept (40 mg/mL) (b) in two rab-
bits’ right eye
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in median baseline serum, vitreous, and aqueous osmo-
larities. Histology and transmission electron microscopy 
showed no major anatomic signs of toxicity, and no cyto-
toxic effect was observed in ARPE-19 cells exposed to 
clinical and 2× clinical concentration of ziv-aflibercept, 
which was also reported by Bababeygy et al. [19, 33]. del 
Carpio et  al. showed that ziv-aflibercept was not detri-
mental to cell viability at a low dose (1/2×) and a clini-
cal equivalent dose for MIO-M1 cells in vitro. However, 
twice the clini-cal dose of ziv-aflibercept reduced Müller 
cell viability, whereas this reduction at 2× clinical dose 
was not observed for ranibizumab, aflibercept, or beva-
cizumab [34].
Recently, de Oliveira Dias et  al. reported the first 
human intravitreal administration of ziv-aflibercept. A 
patient with refractory neovascular AMD was given 2 
monthly intravitreal injections of 0.05  ml ziv-afliber-
cept (1.25 mg) and experienced subjective and objective 
improvement in VA with a decrease in intraretinal and 
subretinal fluid. No ERG changes were noticed when 
baseline and 30-day follow-up were compared. No AE 
were observed at any time point. The therapeutic dose 
of ziv-aflibercept was chosen on the basis of preliminary 
studies that showed efficacy of aflibercept at doses of 
0.5–2  mg. The dose of 1.25  mg was chosen to keep the 
usual volume of 0.05  ml for intravitreal injections. Vol-
umes larger than 0.05 ml may increase the risk of intraoc-
ular pressure [11]. Unpublished data from the DME study 
group from the Federal University of São Paulo showed 
regression of intraretinal fluid in a 49-year-old female 
patient presenting DME, 4  weeks after the third injec-
tion of 0.05  ml of ziv-aflibercept 25  mg/ml (1.25  mg) 
(Figs. 2 and 3 a, b, c). VA improved from 20/100 to 20/40, 
4 weeks after the third injection of ziv-aflibercept.
Mansour et  al. presented recent data on four patients 
with neovascular AMD and two patients with DME 
who received one intravitreal injection of 0.05  ml of 
ziv-aflibercept (1.25  mg). All six patients showed evi-
dence of improvement in VA with no signs of intraocu-
lar inflammation, change in lens status or retinal toxicity 
[17]. Chhablani also reported the intravitreal injection of 
1.25 mg intravitreal ziv-aflibercept in a patient presenting 
with bilateral ME secondary to CRVO, who had already 
received 12 and 13 anti-VEGF injections in the right and 
left eye, respectively, along with one intravitreal triamci-
nolone injection and peripheral panretinal photocoagu-
lation in both eyes. At 1-month follow-up of intravitreal 
ziv-aflibercept injection in both eyes, the patient experi-
enced an improvement in VA along with CRT decrease. 
He did not have any symptoms of blurred vision or ocular 
Fig. 2 Baseline color fundus image (a), fluorescein angiography (b) and SD-OCT (c) of the right eye of a patient presenting DME. a At baseline, hard 
exudates and diffuse intraretinal fluid are seen in the perifoveal area. b At baseline, diffuse hyperfluorescence due to leakage (especially supero-
temporally) and hypofluorescence due to non-perfusion (infero-temporally) are seen in the perifoveal area. c Cystoid spaces and subretinal and 
intraretinal fluid are seen in the foveal and perifoveal area
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pain related to injection or any signs of inflammation/
toxicity [35].
Conbercept
Conbercept (KH902) has been studied in a phase 3 clini-
cal trial and was approved to treat neovascular AMD by 
the China State FDA in December 2013. Conbercept has 
not yet reached the market in other countries [36].
After preclinical results showing the antiangiogenetic 
effects of conbercept, there has been a growing interest 
in using this drug intravitreally to treat VEGF-related 
ophthalmic diseases [12, 20, 36]. The AURORA study was 
a 12-month, randomized, double-masked, controlled-
dose, and interval-ranging phase two clinical trial that 
took place at nine sites in China; it was designed as a 
superiority trial to assess the safety and efficacy of differ-
ent dosing regimens. Eligible patients were randomized 
1:1 to 0.5- or 2.0-mg treatment groups. Initially, all 
patients received monthly intravitreal injections of con-
bercept for a total of three injections. After three loading 
doses of monthly intravitreal conbercept injection, the 
patients were then randomized into the monthly (Q1 M) 
or PRN group. One hundred and twenty-two patients 
were enrolled. At 12  months, mean improvements in 
BCVA from baseline were 14.31, 9.31, 12.42, and 15.43 
letters for the 0.5-mg PRN, 0.5-mg Q1 M, 2.0-mg PRN, 
and 2.0-mg Q1 M regimens, respectively. A reduction in 
CRT was also detected. At 12 months, mean reductions 
in CRT in the four regimens were 119.8, 129.7, 152.1, and 
170.8  μm, respectively. At 12  months follow-up, no sig-
nificant differences in BCVA or anatomic outcomes were 
found between the groups, regardless of the dose or dos-
ing regimen. Overall, conbercept was well tolerated, and 
the incidence of ocular AE was low. The most common 
AE were usually caused by the intravitreal injection pro-
cedure and disappeared with or without treatment. RD 
did not occur in this study. A case of hepatitis suspected 
of being drug induced was identified and thought to be 
caused by an oral supplement, and the hepatitis was cat-
egorized as having no relationship with the study drug 
[12].
A phase 3 trial with intravitreal conbercept for exuda-
tive AMD was completed in 2013, and the results were 
announced at Angiogenesis, Exudation, and Degenera-
tion in 2014 [37, 38]. In this trial, patients in the treat-
ment group received three fixed monthly injections and 
then two sham injections monthly followed by conber-
cept injection every 3 months up to 12 months (intravit-
real con-bercept at 0, 1, 2, 5, 8, and 11 months). Patients 
in the sham injection group were given three monthly 
sham injections and then crossed over to the treat-
ment group. Both groups had a 12-month follow-up 
Fig. 3 Color fundus image (a) fluorescein angiography (b) and SD-OCT (c) of the right eye of the same patient shown in Fig. 2. 4 weeks after 
the 3rd monthly injection of ziv-aflibercept. a 4 weeks after the third ziv-aflibercept injection, a decrease of intraretinal fluid and hard exudates is 
noticed in the perifoveal area of the right eye. b 4 weeks after the third ziv-aflibercept injection, a decrease of leakage is seen in the perifoveal area 
of the right eye. c 4 weeks after the third ziv-aflibercept injection, a decrease in the subretinal and intraretinal fluid is noticed
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period. The report from the Angiogenesis, Exudation, 
and Degeneration meeting in 2014 showed that patients 
exhibited a mean change in BCVA of +10 letters at 
12  months. Morphologic changes observed by OCT 
exhibited a significant reduction in central subfield 
thickness of 79 μm in the treatment groups at 3 months, 
whereas the sham injection group experienced a 
decrease of 44  μm, which was not significant. When 
the sham injection group crossed over to the treatment 
group, similar results were also observed at 12 months 
on OCT and fluorescein angiography. A reduction in 
subretinal fluid maximum height at 3 months was seen 
in the treatment group. After crossing over to the treat-
ment group, 93 % of participants had less than 320 μm 
central subfield thickness at 12 months [20, 37, 38].
Conclusions
Fusion proteins are a promising treatment for ocular dis-
eases related to angiogenesis. They are fully human and 
may have higher affinity, binding VEGF more tightly than 
native receptors or monoclonal antibodies. They block all 
VEGF-A isoforms, VEGF-B, and PlGF, and should pen-
etrate all retinal layers.
Aflibercept, the only United Stated FDA-approved 
fusion protein for ocular diseases, has firmly joined 
ranibizumab and bevacizumab as an important therapeu-
tic option in the management of neovascular AMD, DME 
and RVO. Ziv-aflibercept, a systemic chemotherapeutic 
agent approved for the treatment of metastatic colorec-
tal cancer, has been recently studied as a lower cost alter-
native for the treatment of retinal diseases. Although no 
signs of retinal toxicity were found in patients subjected 
to intravitreal ziv-aflibercept injection, its safety and effi-
cacy still remain to be proved in larger studies. Conber-
cept has also been studied for the treatment of exudative 
AMD in a phase 3 study, showing no signs of retinal tox-
icity, along with an improvement in VA. More data are 
necessary to evaluate the retinal safety and efficacy of 
intravitreal ziv-aflibercept and conbercept.
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